دورية أكاديمية
أعرض في EDS

Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination.

التفاصيل البيبلوغرافية
العنوان: Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination.
المؤلفون: Narayanaswamy V; Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, and Maternal Fetal Medicine and Pioneer Valley Life Sciences Institute, Baystate Medical Center, Springfield, Massachusetts., Pentecost BT, Schoen CN, Alfandari D, Schneider SS, Baker R, Arcaro KF
المصدر: Obstetrics and gynecology [Obstet Gynecol] 2022 Feb 01; Vol. 139 (2), pp. 181-191.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401101 Publication Model: Print Cited Medium: Internet ISSN: 1873-233X (Electronic) Linking ISSN: 00297844 NLM ISO Abbreviation: Obstet Gynecol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2004- : Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: New York.
مواضيع طبية MeSH: Breast Feeding*, Antibodies, Neutralizing/*analysis , COVID-19 Vaccines/*immunology , Cytokines/*analysis , Milk, Human/*chemistry , SARS-CoV-2/*immunology, Adult ; Antibodies, Viral/analysis ; Cohort Studies ; Female ; Humans ; Immunoglobulin A/analysis ; Immunoglobulin G/analysis ; Infant ; Infant, Newborn ; Middle Aged ; Vaccination
مستخلص: Objective: To evaluate immune responses to coronavirus disease 2019 (COVID-19) mRNA-based vaccines present in breast milk and transfer of the immune responses to breastfeeding infants.
Methods: We enrolled 30 lactating women who received mRNA-based COVID-19 vaccines from January through April 2021 in this cohort study. Women provided serial milk samples, including milk expressed before vaccination, across 2-3 weeks after the first dose, and across 3 weeks after the second dose. Women provided their blood, spotted on cards (dried blood spots), 19 days after the first dose and 21 days after the second dose. Stool samples from the breastfed infants were collected 21 days after mothers' second vaccination. Prepandemic samples of milk, dried blood spots, and infant stool were used as controls. Milk, dried blood spots, and infant stool were tested by enzyme-linked immunosorbent assay for receptor-binding domain (RBD)-specific immunoglobulin (Ig)A and IgG. Milk samples were tested for the presence of neutralizing antibodies against the spike and four variants of concern: D614G, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1). Levels of 10 cytokines were measured in milk samples.
Results: Milk from COVID-19-immunized women neutralized the spike and four variants of concern, primarily driven by anti-RBD IgG. The immune response in milk also included significant elevation of interferon-γ. The immune response to maternal vaccination was reflected in breastfed infants: anti-RBD IgG and anti-RBD IgA were detected in 33% and 30% of infant stool samples, respectively. Levels of anti-RBD antibodies in infant stool correlated with maternal vaccine side effects. Median antibody levels against RBD were below the positive cutoffs in prepandemic milk and infant stool samples.
Conclusion: Humoral and cellular immune responses to mRNA-based COVID-19 vaccination are present in most women's breast milk. The milk anti-RBD antibodies can neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike and variants of concern. Anti-RBD antibodies are transferred to breastfed infants, with the potential to confer passive immunity against SARS-CoV-2.
Competing Interests: Financial Disclosure The authors did not report any potential conflicts of interest.
(Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.)
References: Breastfeed Med. 2021 Dec;16(12):987-994. (PMID: 34382820)
Vaccine. 2003 Jul 28;21(24):3374-6. (PMID: 12850343)
Int J Environ Res Public Health. 2021 Aug 21;18(16):. (PMID: 34444579)
Vaccines (Basel). 2021 Jan 18;9(1):. (PMID: 33477534)
Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17. (PMID: 33775692)
Cell Rep. 2021 Jun 29;35(13):109292. (PMID: 34166617)
NPJ Vaccines. 2021 Aug 19;6(1):105. (PMID: 34413319)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Am J Obstet Gynecol. 2021 Jul;225(1):101-103. (PMID: 33798480)
PLoS One. 2017 Feb 23;12(2):e0172763. (PMID: 28231310)
Nature. 2020 Oct;586(7830):516-527. (PMID: 32967006)
mBio. 2021 Feb 9;12(1):. (PMID: 33563823)
Sci Immunol. 2020 Oct 8;5(52):. (PMID: 33033173)
Cell. 2021 Apr 1;184(7):1858-1864.e10. (PMID: 33631096)
iScience. 2020 Nov 20;23(11):101735. (PMID: 33134887)
J Allergy Clin Immunol. 2020 Sep;146(3):467-478. (PMID: 32896307)
Front Immunol. 2020 Sep 30;11:595739. (PMID: 33117408)
J Hum Lact. 2020 Nov;36(4):609-613. (PMID: 32985922)
Breastfeed Med. 2021 Dec;16(12):1004-1009. (PMID: 34427487)
Obstet Gynecol. 2021 Aug 1;138(2):189-197. (PMID: 33910220)
Nat Med. 2021 Apr;27(4):622-625. (PMID: 33654292)
Nature. 2020 Oct;586(7830):594-599. (PMID: 32998157)
JAMA. 2021 May 18;325(19):2013-2014. (PMID: 33843975)
Cell. 2020 Aug 20;182(4):812-827.e19. (PMID: 32697968)
JAMA. 2021 Jun 15;325(23):2370-2380. (PMID: 33983379)
J Hum Lact. 2021 Aug;37(3):492-498. (PMID: 34297643)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662)
Curr Protoc Microbiol. 2020 Jun;57(1):e100. (PMID: 32302069)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288661)
Nutrients. 2018 May 17;10(5):. (PMID: 29772785)
BMC Pregnancy Childbirth. 2021 Sep 17;21(1):632. (PMID: 34535094)
N Engl J Med. 2021 Mar 8;384(15):1466-1468. (PMID: 33684280)
JAMA Netw Open. 2021 Aug 2;4(8):e2120575. (PMID: 34379127)
Acta Paediatr. 2010 Oct;99(10):1517-21. (PMID: 20456265)
Breastfeed Med. 2021 Jan;16(1):2. (PMID: 33372846)
Nutrients. 2019 Apr 24;11(4):. (PMID: 31022910)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):318-324. (PMID: 28906320)
Lancet Respir Med. 2021 Sep;9(9):999-1009. (PMID: 34224675)
معلومات مُعتمدة: R01 CA230478 United States CA NCI NIH HHS; R24 OD021485 United States OD NIH HHS
المشرفين على المادة: 0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (COVID-19 Vaccines)
0 (Cytokines)
0 (Immunoglobulin A)
0 (Immunoglobulin G)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20220201 Date Completed: 20220211 Latest Revision: 20220409
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8759542
DOI: 10.1097/AOG.0000000000004661
PMID: 35104067
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-233X
DOI:10.1097/AOG.0000000000004661